Overview
Maca root (Lepidium meyenii) is a cruciferous plant cultivated in the Peruvian Andes that has been used traditionally for centuries to enhance fertility, libido, energy, and overall vitality. Today, it is one of the most popular botanical supplements on the market, available in powder, capsule, and liquid extract forms. The supplement industry markets maca for sexual dysfunction, hormonal balance, mood improvement, and athletic performance, with a typical monthly cost of $10–$35.
Unlike many herbal supplements, maca has been studied in controlled clinical trials, though the evidence base remains modest in scope. Importantly, maca does not significantly alter circulating sex hormones (testosterone, estrogen, FSH, LH) in most studies—a finding that surprises many users. Instead, its effects appear to be mediated through bioactive compounds called macamides, macaenes, and benzylamine alkaloids that interact with the endocannabinoid system and hypothalamic-pituitary axis signaling. This distinction is critical for understanding what maca can and cannot deliver.
This comprehensive guide covers the current scientific evidence for maca across 15+ health domains, realistic dosing protocols, potential side effects, and safety considerations based on clinical research.
How Maca Root Works: The Mechanism
Maca's effects do not stem from direct hormone elevation. Instead, the supplement operates through several interconnected mechanisms:
Primary Active Compounds
Macamides are unique fatty acid amides found exclusively in maca that appear to inhibit the enzyme fatty acid amide hydrolase (FAAH). This inhibition preserves endocannabinoid tone—the activity of the body's endocannabinoid system—which influences mood, libido, pain perception, and stress response. This mechanism explains why maca may improve sexual function and mood without raising testosterone.
Benzylamine alkaloids and macaenes appear to modulate signaling in the hypothalamic-pituitary axis, the master regulatory system governing reproduction, stress hormones, and energy metabolism, without directly forcing hormone production upward.
Secondary Mechanisms
Maca contains exceptionally high levels of micronutrients, flavonoids, and plant sterols that may support adrenal function and reduce cortisol-related fatigue. The supplement's antioxidant and anti-inflammatory compounds also contribute to its broad effects across metabolism, immunity, and neuroprotection.
Evidence by Health Goal
Evidence for each health goal is organized by evidence tier, ranging from Tier 1 (strongest) to Tier 3 (probable but limited). This structure helps you understand the confidence level for each claim.
Sexual Health — Tier 3 (Probable)
Maca shows the most consistent human evidence for sexual outcomes, with multiple small RCTs demonstrating improvements in erectile function, sexual desire, and satisfaction.
- Erectile dysfunction: Men with mild ED taking 2,400 mg of maca daily improved their IIEF-5 score by 1.6±1.1 points versus 0.5±0.6 in placebo (n=50, p<0.001), representing a clinically meaningful improvement.
- SSRI-induced sexual dysfunction: A dose-finding RCT found that 3.0 g daily maca significantly improved the Arizona Sexual Experience Scale (ASEX) from 22.8±3.8 to 16.9±6.2 (n=16, p=0.028), helping individuals with antidepressant-induced sexual side effects.
- Sexual desire in healthy men: An 8–12 week double-blind RCT showed that maca improved sexual desire in 57 healthy men independent of changes in testosterone or estradiol—a finding reinforcing that maca does not work by elevating sex hormones.
Hormonal Balance — Tier 3 (Probable)
Maca demonstrates probable efficacy for reproductive markers and menopausal symptoms, but it does so without altering serum hormone levels—a counterintuitive finding with important clinical implications.
- Hypogonadism symptoms: An 80-patient, 12-week RCT found that 3,000 mg daily maca significantly improved the Aging Males' Symptoms (AMS) scale and erectile function scores (IIEF, IPSS) versus placebo (p<0.05), with ADAM positive rates declining significantly (p<0.0001).
- Menopausal symptoms: A 14-woman crossover RCT showed that 3.5 g daily maca for 6 weeks significantly reduced Greene Climacteric Scale scores (a measure of menopausal anxiety, depression, and vasomotor symptoms) versus placebo—all without changes in serum estradiol, FSH, LH, or SHBG.
Mood & Stress — Tier 3 (Probable)
Limited human evidence supports modest benefits for mood and anxiety, primarily from small RCTs and observational studies.
- Psychological symptoms and anxiety: Postmenopausal women receiving 3.5 g daily maca for 6 weeks showed significant reductions in psychological symptoms and anxiety on the Greene Climacteric Scale versus placebo (n=14, p<0.05).
- Energy and mood in general populations: A randomized controlled trial of 175 participants receiving 3 g daily red or black maca extracts over 12 weeks reported improvements in mood and energy, with red maca showing superior effects compared to black maca.
Heart Health — Tier 3 (Probable)
Two small RCTs and observational studies suggest maca may reduce blood pressure and improve cardiovascular metabolic markers, though evidence remains incomplete.
- Blood pressure: Postmenopausal women taking 3.3 g daily maca for 6 weeks showed significant reductions in diastolic blood pressure (p<0.05, n=29).
- Inflammatory markers: A cross-sectional study of 50 participants found that maca consumers had significantly lower serum IL-6 levels than non-consumers (p<0.05) and higher overall health status scores (p<0.01).
Joint Health — Tier 3 (Probable)
A single human RCT supports maca's use for osteoarthritis symptom relief, with evidence of chondroprotective mechanisms in laboratory studies.
- Osteoarthritis pain relief: A polyherbal formula containing maca (RNI 249) achieved a 94% response rate (≥20% WOMAC pain reduction) in osteoarthritis patients versus 89% for glucosamine sulfate, with improvements noted within 1 week (p<0.05, n=95). Notably, this study did not test maca alone.
- Chondrocyte signaling: In vitro, maca extract increased IGF-1 mRNA expression 2.7-fold in human chondrocytes and 3.8-fold when combined with cat's claw, despite IL-1β-induced inflammation (p<0.05).
Anti-Inflammation — Tier 2 (Potential)
Maca shows anti-inflammatory effects in cell and animal studies, with one human observational study but limited RCT evidence.
- Serum inflammatory markers: A 50-person observational study found that maca consumers had significantly lower IL-6 levels (p<0.05) and lower chronic mountain sickness scores compared to non-consumers.
- RCT limitations: A 29-person, 6-week crossover RCT using 3.3 g daily found no significant differences in serum cytokines (IL-6, TNF-α, TNF-β) versus placebo, despite improvements in diastolic blood pressure and depression scores—suggesting maca's benefits may operate through mechanisms beyond direct cytokine suppression.
Athletic Performance — Tier 3 (Probable)
Animal models show large effect sizes for grip strength and endurance, but human evidence is mixed and limited.
- Animal data: A meta-analysis of 21 animal studies found large effect sizes for grip strength (SMD=5.23), rota-rod performance (SMD=6.26), and blood lactate reduction (SMD=-1.70).
- Human evidence limitation: A 10-person RCT in basketball players taking 2,000 mg daily maca for 2 weeks showed NO significant improvements in countermovement jump height (p=0.352), fatigue index (p=0.266), or blood lactate clearance (p=0.258) versus placebo.
Energy — Tier 2 (Potential)
While animal models suggest anti-fatigue potential, the single human RCT testing energy outcomes found no benefit.
- Failed human trial: The basketball player study mentioned above found no improvements in fatigue-related measures despite using a relatively high dose (2,000 mg daily).
- Animal promise: Rat studies found that maca polysaccharides improved energy metabolism enzyme levels, corrected lipid metabolism, and regulated glucose metabolism pathways.
Immune Support — Tier 2 (Potential)
One human RCT showed increased interferon-γ secretion after exhaustive exercise, but broader immune outcomes remain unproven.
- Interferon-γ production: Healthy men taking 2.25 g twice daily (4.5 g total) for 12 weeks showed significantly increased interferon-γ secretion from immune cells immediately and 24 hours post-exercise versus placebo (n=20, p<0.05).
- Cytokine inconsistency: The same 29-person RCT noting blood pressure improvements found no significant changes in resting serum cytokines, suggesting maca may prime immune response to acute stimulus rather than altering baseline inflammation.
Cognition — Tier 2 (Potential)
Animal and in vitro studies show neuroprotection, but human evidence is minimal and non-specific.
- Neuroprotection in animal models: Macamide B pretreatment decreased brain infarction volume and improved neural recovery in neonatal hypoxic-ischemic brain damage models in mice.
- Lack of human cognitive trials: No human RCTs directly measure cognitive outcomes like memory, processing speed, or executive function.
Longevity — Tier 2 (Potential)
Animal studies suggest mitochondrial benefits, but human longevity evidence is indirect and limited to hypogonadism studies.
- Mitochondrial function: Middle-aged mice (14 months old) receiving 5 weeks of maca powder showed improved cognitive function and motor coordination accompanied by increased mitochondrial respiratory function in the cortex (n=14).
- Age-related symptoms in men: The 80-person hypogonadism trial showed improvements in aging-related symptoms using the AMS scale, though this measures symptom burden rather than lifespan or healthspan.
Liver Health — Tier 2 (Potential)
Animal models demonstrate hepatoprotective effects, but no human clinical trials exist.
- Hepatotoxicity reversal: Maca polysaccharide reduced serum transaminase elevation and improved pathological liver changes in cyclophosphamide-induced hepatotoxicity mice, activating the hepatic NRF-2/GPX/SOD antioxidant system.
- Hepatitis protection: Maca polysaccharide suppressed inflammatory cytokine production (IFN-γ, TNF-α, IL-1β, IL-6, IL-12, IL-17a) and ameliorated acute liver injury in concanavalin A-induced hepatitis in mice via NF-κB and STAT pathway inhibition.
Gut Health — Tier 2 (Potential)
Emerging animal and in vitro data suggest prebiotic effects, but human trials are absent.
- Microbiota modulation: Maca protein alleviated colitis symptoms in mice by reducing colon tissue damage and inflammatory markers while restoring dysbiotic microbiota composition.
- Beneficial bacteria promotion: Maca polysaccharides significantly increased the relative abundance of beneficial Bacteroidetes and inhibited harmful Escherichia-Shigella in in vitro human gut fermentation studies using human fecal samples.
Skin & Hair — Tier 2 (Potential)
Animal and in vitro studies suggest wound healing and tyrosinase inhibition, but no human skin or hair trials exist.
- Wound healing acceleration: Topical red maca extract accelerated wound closure, decreased epidermal hyperplasia, and reduced inflammatory cell infiltration in mice.
- Melanin regulation: Grey maca phenotype extracts inhibited tyrosinase activity at 72.86% (water extract) and 75.66% (chloroform extract) in vitro, suggesting potential skin-lightening properties.
Fat Loss — Tier 2 (Potential)
Animal models show metabolic benefits, but zero human fat loss trials exist.
- Insulin signaling in rodents: Rats fed a high-fat diet plus maca (40 mg/kg/day) showed significantly increased fat tissue IRS1 expression (p<0.0001) and highest SIRT1 levels in maca-supplemented groups (p<0.01) after 60 days (n=28).
- Hepatic protection from metabolic stress: Red maca extract prevented acrylamide-induced oxidative stress and reduced liver enzyme markers (ALT and AST) in a dose-dependent manner in rats.
Muscle Growth — Tier 2 (Potential)
Animal models and bioactive compound profiles suggest antioxidant and anti-inflammatory benefits, but no human muscle hypertrophy trials exist.
- Performance metrics in animals: The meta-analysis of 16 animal studies found grip strength improvements with very large effect size (SMD=5.23) and rota-rod motor endurance with very large effect size (SMD=6.26).
Injury Recovery — Tier 2 (Potential)
Animal and in vitro studies suggest wound healing and anti-inflammatory potential, but human evidence is minimal.
- Brain injury protection: MCH1, an isolated macamide with high FAAH inhibition, reduced infarction area in motor cortex-related regions in rats following ischemic stroke but did not improve neurological recovery scores or sensorimotor function at 10 days.
- Wound healing: Topical red maca extract accelerated wound closure and reduced epidermal hyperplasia in mice at both sea level and high altitude.
Sleep — Tier 1 (No Evidence)
No human evidence demonstrates that maca affects sleep. Current literature only identifies this as an area needing investigation due to maca's documented stimulant properties, which theoretically raise questions about potential sleep disruption if taken in the evening.